Skip to main content
Clinical Trials/NCT05715749
NCT05715749
Completed
N/A

Exploring the Feasibility and Utility of In-home Body Weight Support Harness System Use in Children Treated for Spinal Muscular Atrophy: a Pilot Study

Nationwide Children's Hospital1 site in 1 country33 target enrollmentSeptember 7, 2018

Overview

Phase
N/A
Intervention
Not specified
Conditions
Spinal Muscular Atrophy Type I
Sponsor
Nationwide Children's Hospital
Enrollment
33
Locations
1
Primary Endpoint
Change in Revised Hammersmith Scale (RHS)
Status
Completed
Last Updated
last year

Overview

Brief Summary

The goal of this pilot interventional study is to learn about the use of an in-home harness system in children who have been treated for spinal muscular atrophy. The main questions it aims to answer are:

  1. Is the in-home body weight support harness system a feasible option for families to use?
  2. Is the in-home body weight support harness system a useful tool for children treated for spinal muscular atrophy?
  3. Is the in-home body weight support harness system a safe tool for children treated for spinal muscular atrophy?

Participants will be given an in-home body weight support harness system and taught how to use it. Families will document how often and for how long they use the system over 6 months. Children will be given tests of motor function at the beginning, 3-months, and 6-months. At the end of the study, families will be asked to fill out a questionnaire about thier experience using the system.

Registry
clinicaltrials.gov
Start Date
September 7, 2018
End Date
July 15, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Megan Iammarino

Research Physical Therapist

Nationwide Children's Hospital

Eligibility Criteria

Inclusion Criteria

  • Confirmed heterozygous mutation in SMN1 gene and 2 or 3 copies of SMN2 (historically, SMA Type 1 and Type 2)
  • Past or current treatment with nusinersen, onasemnogene abeparvovec, or risdiplam
  • Upright head control (defined as the ability to lift head from full forward flexion)
  • Weight under or 50lbs
  • Confirmed motor delay

Exclusion Criteria

  • 4+ copies of SMN2 (historically, SMA Type 3 and 4)
  • Evidence of lower limb injury or recent fracture
  • In the opinion of the investigator, it was unsafe for the child to participate

Outcomes

Primary Outcomes

Change in Revised Hammersmith Scale (RHS)

Time Frame: Completed at baseline, 3 months, and 6 months

A disease-specific and performance-based outcomes originally developed to measure motor skill in untreated individuals with SMA, revised following Rasch analysis of HFMSE. Scores range from 0 - 69 points; higher scores reflect a greater level of function. An increase in score indicates a better outcome.

Change in World Health Organization Motor Milestone Checklist

Time Frame: Completed at baseline, 3 months, and 6 months

A checklist of key gross motor milestones expected during typical development. Scores can range from 0 - 6 milestones achieved. Achievement of a greater number of milestones indicates better outcomes.

Caregiver survey

Time Frame: End of study visit (month 6)

A five question likert-style survey asking families to rate their experience during the study. The scales asks the family to rate (1) the perceived impact of BWSS on motor and (2) non-motor skills, (3) the child's perceived enjoyment using the system, (4) the ease of equipment use, and (5) if the family believed that use of the BWSS was beneficial on a 5-point Likert scale; scores of 4 or 5 were considered favorable, scores of 3 were considered neutral, and scores of 1 or 2 were considered unfavorable. Higher scores indicate greater perceived benefit of participation.

Change in Hammersmith Functional Motor Scale Expanded (HFMSE)

Time Frame: Completed at baseline, 3 months, and 6 months

A disease-specific and performance-based outcomes originally developed to measure motor skill in untreated individuals with SMA. Scores range from 0 - 66 points; higher scores reflect a greater level of function. An increase in score indicates a better outcome.

Change in The Neuromuscular Gross Motor Outcome (GRO) scale

Time Frame: Completed at baseline, 3 months, and 6 months

A 50-item performance-based outcome developed to quantify motor function across the span of age and abilities in individuals with neuromuscular disorders including spinal muscular atrophy (SMA). Scores range from 0 - 100 points; higher scores reflect a greater level of function. An increase in score indicates a better outcome.

Change in Bayley Scales of Infant and Toddler Development 3rd ed. (Bayley-III), Gross motor subtest

Time Frame: Completed at baseline, 3 months, and 6 months

A norm-referenced developmental assessment of gross motor skill in children 16 days - 3.5 years of age. Raw scores range from 0 - 72. Higher scores indicate a greater level of funcion. An increase in score indicates a better outcome.

Secondary Outcomes

  • Harness use log(Completed throughout 6-month study period)

Study Sites (1)

Loading locations...

Similar Trials